image
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
Pier Vincenzo Piazza, CEO
Latest News
A New Chapter for Aelis Farma - Inauguration of New Headquarters in the Center of Bordeaux
December 2023
+
Aelis Farma announces positive results of non-clinical studies required by regulatory agencies to enter its first CB1-SSi, AEF0117, in phase 3 clinical trial...
November 2023
+